Photodynamic therapy of cutaneous T-cell lymphoma cell lines mediated by 5-aminolevulinic acid and derivatives

被引:7
|
作者
Vallecorsa, Pablo [1 ]
Di Venosa, Gabriela [1 ]
Gola, Gabriel [2 ,3 ]
Saenz, Daniel [1 ]
Mamone, Leandro [1 ]
MacRobert, Alexander J. [4 ]
Ramirez, Javier [2 ,3 ]
Casas, Adriana [1 ]
机构
[1] CONICET Hosp Clin Gral, Ctr Invest Porfirinas & Porfirias CIPYP, Buenos Aires, DF, Argentina
[2] Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Organ, Buenos Aires, DF, Argentina
[3] Univ Buenos Aires, CONICET, Unidad Microanal & Metodos Fis Aplicados Quim Org, Buenos Aires, DF, Argentina
[4] UCL, Ctr Nanomed & Surg Theranost, UCL Med Sch, Rowland Hill St, London NW3 2PF, England
关键词
Photodynamic therapy; Porphyrins; Cancer; Cutaneous T-cell lymphoma; Mycosis fungoides; Sezary syndrome; AMINOLEVULINIC-ACID; MYCOSIS-FUNGOIDES; PORPHYRINS; ALA; LYMPHOCYTES; DERMATOLOGY; GROWTH; CANCER; ESTERS;
D O I
10.1016/j.jphotobiol.2021.112244
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The delta-amino acid 5-aminolevulinic acid (ALA), is the precursor of the endogenous photosensitiser Protoporphyrin IX (PpIX), and is currently approved for Photodynamic Therapy (PDT) of certain superficial cancers. However, ALA-PDT is not very effective in diseases in which T-cells play a significant role. Cutaneous T-cell lymphomas (CTCL) is a group of non-Hodgkin malignant diseases, which includes mycosis fungoides (MF) and Se acute accent zary syndrome (SS). In previous work, we have designed new ALA esters synthesised by three-component Passerini reactions, and some of them showed higher performance as compared to ALA. This work aimed to determine the efficacy as pro-photosensitisers of five new ALA esters of 2-hydroxy-N-arylacetamides (1f, 1 g, 1 h, 1i and 1 k) of higher lipophilicity than ALA in Myla cells of MF and HuT-78 cells of SS. We have also tested its effectiveness against ALA and the already marketed ALA methyl ester (Me-ALA) and ALA hexyl ester (He-ALA). Both cell Myla and SS cells were effectively and equally photoinactivated by ALA-PDT. Besides, the concentration of ALA required to induce half the maximal porphyrin synthesis was 209 mu M for Myla and 169 mu M for HuT-78 cells. As a criterion of efficacy, we calculated the concentration of the ALA derivatives necessary to induce half the plateau porphyrin values obtained from ALA. These values were achieved at concentrations 4 and 12 times lower compared to ALA, according to the derivative used. For He-ALA, concentrations were 24 to 25 times lower than required for ALA for inducing comparable porphyrin synthesis in both CTCL cells. The light doses for inducing 50% of cell death (LD50) for He-ALA, 1f, 1 g, 1 h and 1i were around 18 and 25 J/cm(2) for Myla and HuT-78 cells respectively, after exposure to 0.05 mM concentrations of the compounds. On the other hand, the LD50s for the compound 1 k were 40 and 57 J/cm(2) for Myla and HuT-78, respectively. In contrast, 0.05 mM of ALA and Me-ALA did not provoke photokilling since the concentration employed was far below the porphyrin saturation point for these compounds. Our results suggest the potential use of ALA derivatives for topical application in PDT treatment of MF and extracorporeal PDT for the depletion of activated T-cells in SS.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] AMINOLEVULINIC ACID IN PHOTODYNAMIC THERAPY OF CUTANEOUS T-CELL LYMPHOMA
    WOLF, P
    FINKPUCHES, R
    CERRONI, L
    KERL, H
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1994, 102 (04) : 602 - 602
  • [2] 5-Aminolevulinic acid (ALA) mediated photodynamic therapy of bladder cancer cell lines
    Fickweiler, S
    Krieg, R
    Stepp, H
    Hofstaedter, F
    Knuechel, R
    [J]. PHOTOHEMOTHERAPY OF CANCER AND OTHER DISEASES, PROCEEDINGS, 1999, 3563 : 143 - 147
  • [3] Derivatives of 5-Aminolevulinic Acid for Photodynamic Therapy
    Donnelly, Ryan F.
    McCarron, Paul A.
    Woolfson, A. David
    [J]. PERSPECTIVES IN MEDICINAL CHEMISTRY, 2007, 1 : 49 - 63
  • [4] PHOTODYNAMIC THERAPY WITH TOPICAL DELTA-AMINOLEVULINIC-ACID FOR TREATMENT OF CUTANEOUS CARCINOMAS AND CUTANEOUS T-CELL LYMPHOMA
    SHANLER, SD
    WAN, W
    WHITAKER, JE
    MANG, TS
    JONES, C
    WILSON, BD
    STOLL, H
    OSEROFF, AR
    [J]. CLINICAL RESEARCH, 1993, 41 (02): : A511 - A511
  • [5] PHOTODYNAMIC THERAPY WITH TOPICAL DELTA-AMINOLEVULINIC-ACID FOR TREATMENT OF CUTANEOUS CARCINOMAS AND CUTANEOUS T-CELL LYMPHOMA
    SHANLER, SD
    WAN, W
    WHITAKER, JE
    MANG, TS
    JONES, C
    WILSON, BD
    STOLL, H
    OSEROFF, AR
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1993, 100 (04) : 602 - 602
  • [6] Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application
    Orenstein, A
    Haik, J
    Tamir, J
    Winkler, E
    Trau, H
    Malik, Z
    Kostenich, G
    [J]. DERMATOLOGIC SURGERY, 2000, 26 (08) : 765 - 769
  • [7] 5-Aminolevulinic Acid-mediated Photodynamic Therapy on Primary Bone Tumor and Bone Metastases Cell Lines
    Sachsenmaier, Saskia Magdalen
    Walter, Christian
    Liang, Chen
    Riester, Rosa
    Wulker, Nikolaus
    Danalache, Marina
    [J]. JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2022, (183):
  • [8] Topical 5-aminolevulinic acid-mediated photodynamic therapy for basal cell carcinoma
    Filonenko, E.
    Kaprin, A.
    Urlova, A.
    Grigorievykh, N.
    Ivanova-Radkevich, V
    [J]. PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, 2020, 30
  • [9] Application of Photodynamic Therapy with 5-Aminolevulinic Acid to Extracorporeal Photopheresis in the Treatment of Cutaneous T-Cell Lymphoma: A First-in-Human Phase I/II Study
    Christensen, Eidi
    Foss, Olav Andreas
    Holien, Toril
    Juzenas, Petras
    Peng, Qian
    [J]. PHARMACEUTICS, 2024, 16 (06)
  • [10] Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application - Commentary
    Lambert, WC
    Schwartz, RA
    [J]. DERMATOLOGIC SURGERY, 2000, 26 (08) : 769 - 770